Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

Recruiting now · Phase 1

Conditions studied: Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione

In brief

Chemotherapeutic agents exert significant immunomodulatory effects by influencing tumor-infiltrating immune cells. However, the sequence and combination of chemotherapy regimens differentially modulate immune cell dynamics, ultimately impacting treatment efficacy and patient survival. Glutathione, a critical bioactive molecule, demonstrates broad potential in tumor immunotherapy. Through mechanisms such as scavenging free radicals, modulating immune cell proliferation and differentiation, and regulating cytokine expression, glutathione achieves precise modulation of immune responses to enhance immune system functionality. To investigate whether glutathione can enhance the clinical efficacy of current chemo-immunotherapy regimens in non-small cell lung cancer (NSCLC), investigators conducted this clinical study.

Key facts

Study ID

NCT06896422

Run by

The First Affiliated Hospital of Zhengzhou University

People needed

80

Starts

2025-06-01

Expected to finish

2027-12-31

Last updated by the study team

2025-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed diagnosis of lung squamous cell carcinoma or adenocarcinoma.
• Documented disease progression following first-line chemotherapy or chemo-immunotherapy.
• Age ≥18 years at the time of enrollment.

You may not qualify if…

• Patients with small cell lung cancer or other histological subtypes of lung cancer.
• Patients lost to follow-up, who discontinued treatment, or died within one year of diagnosis.
• Pregnant or lactating women

Where it is running

• the First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.